Analysts Impressed By Amryt As EB Drug Action Date Approaches
Irish Group Raises Revenue Guidance For 2021
Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.
You may also be interested in...
Amryt Optimistic For Year Ahead Despite Filsuvez CRL Setback
The rare disease firm hopes continued growth of key products Myalept and Mycapssa will bolster 2022 revenues as it contends with a US regulatory delay for Filsuvez.
Ambitious Amryt To File Butterfly Skin Drug Imminently
The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.
UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.